Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation

BACKGROUND: China, which has the largest chronic hepatitis B virus (HBV) burden, may expand antiviral therapy to attain the World Health Organization (WHO)-2030 goal of 65% reduction in mortality. We evaluated health outcomes and cost-effectiveness of chronic HBV infection treatments based on alanin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Sihui, Wang, Chao, Liu, Bei, Lu, Qing-Bin, Shang, Jia, Zhou, Yihua, Jia, Jidong, Xu, Xiaoyuan, Rao, Huiying, Han, Bingfeng, Zhao, Tianshuo, Chen, Linyi, Xie, Mingzhu, Cui, Jiahao, Du, Juan, zeng, Jing, huang, Ninghua, Liu, Yaqiong, Zhang, Lei, Zhuang, Hui, Cui, Fuqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326688/
https://www.ncbi.nlm.nih.gov/pubmed/37424693
http://dx.doi.org/10.1016/j.lanwpc.2023.100738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326688/
https://www.ncbi.nlm.nih.gov/pubmed/37424693
http://dx.doi.org/10.1016/j.lanwpc.2023.100738

Ejemplares similares